

The Preparation of 1,2,3-Trisubstituted Guanidines

by Alan R. Katritzky*, Niveen M. Khashab, and Sergey Bobrov

Center for Heterocyclic Compounds, University of Florida, Department of Chemistry, Gainesville, Florida 32611-7200, USA (e-mail: Katritzky@chem.ufl.edu)

Submitted to honor the 85th birthday of *Rolf Huisgen*: inspiring chemist and good friend


An operationally straightforward and efficient benzotriazole-based method for the guanylation of diverse amines by use of the new reagent classes (bis-benzotriazol-1-yl-methylene)amines **13a–13f** and benzotriazole-1-carboxamides **17a–17i** is described. The preparation is described for a variety of both acyclic and cyclic 1,2,3-trisubstituted guanidines in high yields.

Introduction. – A wide variety of structurally diverse molecules that incorporate guanidine units have been isolated from many microorganisms and higher plants [1]. Guanidines are core features of many therapeutically active compounds [2–7], and guanidine alkaloids exhibit antiviral, antifungal, and antitumor activities [1]. Thus, procedures for the preparation of guanidines [8] are of great interest in medicinal chemistry, and much effort has been directed towards efficient syntheses of these compounds (see, e.g., [9]).

The synthesis of guanidines **3** is complicated by their high basicity and nucleophilicity. Many syntheses utilize intermediates with easily removed protective groups. Common methods for the preparation of guanidines **3** involve attack of an amine **1** on various activated guanidinyllating reagents **2a–2j** (*Scheme 1*). Primary amines react smoothly and efficiently with these reagents, whereas sterically more demanding secondary or electronically deactivated aromatic amines face various difficulties.


Methods for the preparation of guanidines **3** (*Scheme 1*) include: *i*) reaction of various ureas **2a** with phosgene then treating the resultant *Vilsmeier* salt with amines **1** [10]; *ii*) using triflicguanidines **2b** as guanidinyllating reagents [11], or *iii*) guanylpiperazine **2c** as guanidinyllating reagents [12]. Several common routes to **3** involve the treatment of amines with electrophilic species **2d–2i** generated from thioureas: *iv*) sulfonic acids **2d** derived from *N*-alkyl-substituted thioureas [13]; *v*) *S*-methyl(aryl)-sulfanylisothiureas **2e** [14], in the presence of Hg salts; *vi*) bis-Boc-isothiureas **2f** and HgCl₂ [15–18]; *vii*) bis-Boc-thioureas **2g** and *Mukaiyama's* Reagent to form a carbodiimide subsequently treated with amines [19]; *viii*) acylthioureas **2h** and amines in the presence of the water-soluble carbodiimide, EDCI (= 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochloride), [20]; *ix*) *S*-methylisothiurea **2i** in refluxing *t*-BuOH with aryl amines [21][22]; or *x*) other guanidinyllating reagents including 1*H*-imidazole-1-carboxamides **2j** [23], and 1,3-diarylthioureas **5** with iminophosphoranes **4** to form trisubstituted guanidines **3** [24].

Scheme 1



Our group introduced benzotriazole-based guanylation reagents: *i*) 1*H*-benzotriazole-1-carboxamidinium *p*-toluenesulfonate **6** [25], *ii*) (1*H*-benzotriazolyl)carboximidoyl chlorides **7** [26], and *iii*) bis(1*H*-benzotriazolyl)carboximidamides **8a** and **8b** (Scheme 2) [27]. Reagents **6–8** guanylate primary and secondary amines under mild conditions in high yields (Scheme 2). 1*H*-Benzotriazole-1-carboxamidinium *p*-tolu-

Scheme 2



enesulfonate **6** affords mono- and *N,N*-disubstituted guanidines (55–86%). Stable, odorless (*1H*-benzotriazolyl)carboximidoyl chlorides **7** allow the preparation of unsymmetric polysubstituted guanidines (45–92%). Bis(*1H*-benzotriazolyl)carboximidamide **8a** enables the synthesis of tri- and tetra-substituted-guanidines from a wide variety of amines. Bis(*1H*-benzotriazolyl)carboximidamides **8b** are efficient for the preparation of acylguanidines (48–85%) [28].

To provide for the facile preparation of polysubstituted guanidines (*cf.* *Scheme 3*, and *Tables 1* and *3*), we have now introduced convenient *1H*-benzotriazole-based guanylation using novel [bis(*1H*-benzotriazol-1-yl)methylidene]amines **13** and *1H*-benzotriazole-1-carboxamidines **17**.

Results and Discussion. – [Bis(*1H*-benzotriazol-1-yl)methylidene]amines **13a–13f** were prepared from bis(*1H*-benzotriazol-1-yl)methanethione (**15**) and triphenylphosphine imides **14a–14f** in toluene at 70° for 3 h and purified by column chromatography (*Scheme 3*). Known triphenylphosphine imides **14a–14g** were synthesized in quantitative yields from the reaction of the corresponding organic azides with Ph₃P in EtOH at reflux for 2 h [29]. Melting points and spectral data for **14a–14g** were identical to reported values (see the *Exper. Part*). The structures of novel **13a–13e** were supported by their ¹H- and ¹³C-NMR spectra, and elemental analysis data (see the *Exper. Part*). Known **13f** was previously been synthesized by a different method [28].

Syntheses of symmetric guanidines **11a–11e** from **13a–13e** and aliphatic primary amines were accomplished in high yields on refluxing in toluene for 1 h (*Scheme 3* and *Table 1*). Compound **11a** was prepared earlier [30]; novel **11b–11e** were fully characterized on the basis of ¹H- and ¹³C-NMR spectroscopy, and elemental analysis. However, we failed to prepare symmetric guanidines corresponding to **11** from **13a–13e** and secondary amines; possibly because, with secondary amines, carbodiimide **10** formation [31] by elimination of *1H*-benzotriazole from an intermediate analogous to **9** is not possible (*Scheme 3*).

Table 1. Preparation of Symmetric and Cyclic Trisubstituted Guanidines **11a–11e** and **19a–19e**

13	R	Product	R ¹	Yield [%]	13	R	Diamine 18	Product	Yield [%]
13a	Ph	11a	Cyclohexyl	79	13b	<i>p</i> -Tol	NH ₂ (CH ₂) ₃ NH ₂	19a	95
13b	<i>p</i> -Tol (4-Me–C ₆ H ₄)	11b	Bu	83	13c	<i>p</i> -Tol	NH ₂ (CH ₂) ₂ NH ₂	19b	95
13c	3-CN–C ₆ H ₄	11c	<i>i</i> -Pr	87	13e	4-Cl–C ₆ H ₄	(NH ₂ CH ₂) ₂ CMe ₂	19c	96
13d	4-EtOCO–C ₆ H ₄	11d	PhCH(Me)	91	13a	Ph	NH ₂ (CH ₂) ₃ NHMe	19d	89
13e	4-Cl–C ₆ H ₄	11e	Bn	85	13f	PhCO	NH ₂ (CH ₂) ₃ NH ₂	19e	77

Reagents **13a** and **13b** and **13f** also successfully guanylated diamines **18** to give cyclic trisubstituted guanidines **19a–19e** in high yields (*Scheme 3* and *Table 1*). The structures of novel **19a**, **19c**, and **19d** were supported by their ¹H- and ¹³C-NMR spectra, and elemental-analysis data. For known **19b** [32] and **19e** [33], the ¹H- and ¹³C-NMR spectra data are now given, they were previously unreported (see the *Exper. Part*).

Preparation of intermediates **16a–16h** was achieved by a simple one step reaction of bis(*1H*-benzotriazol-1-yl)methanethione (**15**) and appropriate primary amines in CH₂Cl₂ at 20° (*Scheme 3*) [34]. Melting points for known **16a**, **16f**, and **16h** were found

to be identical to reported values (see the *Exper. Part*). Novel **16b–e**, and **16g** were characterized by ^1H - and ^{13}C -NMR spectra, and elemental analyses (see the *Exper. Part*). Synthesis of **17a–17l** was achieved from the reaction of **16a–16h** with triphenylphosphine imides **14a–14g** in refluxing toluene for 1 h (*Scheme 3* and *Table 2*). Novel 1*H*-benzotriazole-1-carboximidamides **17a–17l** were identified by ^1H - and ^{13}C -NMR spectra, and elemental analyses (see the *Exper. Part*). Attempts to prepare bis(1*H*-benzotriazol-1-yl-methylene)amines **17** by the reaction of **16a** and **16b** with **14** when R Ts or 4-NO₂-C₆H₄ failed, apparently due to the strong electron-withdrawing nature of these groups (*Scheme 3*). In addition, our efforts to prepare analog of **17** from **16b** (R¹ = *i*-Pr) also failed to give the corresponding *N,N'*-substituted thiourea.

Table 2. Preparation of Guanylation Reagents **17a–17l**

Reactants 16 + 14	R ¹	R	Product 17	Yield [%]
16a + 14a	Bn	Ph	17a	91
16a + 14b	Bn	<i>p</i> -Tol	17b	96
16b + 14b	<i>i</i> -Pr	<i>p</i> -Tol	17c	92
16b + 14e	<i>i</i> -Pr	4-Cl-C ₆ H ₄	17d	67
16c + 14g	Ph	Mesityl	17e	80
16d + 14d	Bu	4-EtOCO-C ₆ H ₄	17f	53
16d + 14g	Bu	Mesityl	17g	84
16e + 14c	Ph(CH ₂) ₂	3-CN-C ₆ H ₄	17h	95
16f + 14e	Cyclohexyl	4-Cl-C ₆ H ₄	17i	40
16g + 14b	2-Methylbutyl	<i>p</i> -Tol	17j	82
16h + 14e	(Furan-2-yl)methyl	4-Cl-C ₆ H ₄	17k	93
16d + 14e	Bu	4-Cl-C ₆ H ₄	17l	87

Secondary amines (see R² and R³ for amines in *Table 3*) underwent efficient guanylation using reagents **17a**, **17b**, **17f**, **17g**, **17h**, and **17i** in toluene under reflux for 12 h to afford unsymmetric guanidines **12a–12f** (*Scheme 3* and *Table 3*). The 1*H*-benzotriazole group in **17a–17c**, **17e**, **17j**, and **17k** was displaced by primary alkylamines in refluxing toluene in just 1 h to form unsymmetric guanidines **20a–20f** in high yields (*Scheme 3* and *Table 3*). The 1*H*-benzotriazole formed as a by-product was removed by washing with saturated aqueous Na₂CO₃. Novel compounds **12a–12f** and **20a–20f** were fully characterized by ^1H - and ^{13}C -NMR spectroscopy, and elemental analyses. The hydroscopic nature of guanidines **12a–12f** and **20a–20f** caused difficulties in obtaining the elemental analyses. For this reason, compounds **12c** and **12d**, and **20e** and **20f** were characterized by elemental analyses of the corresponding hydrochlorides (see the *Exper. Part*).

In summary, new routes for the guanylation of a series of structurally varied primary and secondary amines have been reported. [Bis(1*H*-benzotriazol-1-yl)methylidene]-amines **13a–13f** and 1*H*-benzotriazole-1-carboximidines **17a–17l** are stable, crystalline guanylation reagents that can be stored at room temperature for many weeks with no apparent loss of activity. The preparation of reagents of type **13** and **17** is facile and should find widespread use in the synthesis of guanidines. An attractive feature of this methodology is that 1*H*-benzotriazole, which is generated as a by-product, can be easily

Table 3. Preparation of Substituted Unsymmetrical Guanidines **12a–12f** and **20a–20f**

17	R	R ¹	R ²	R ³	Product	Yield [%]
17a	Ph	Bn	i-Pr	i-Pr	12a	67
17b	<i>p</i> -Tol	Bn		–(CH ₂) ₂ O(CH ₂) ₂ –	12b	90
17f	4-EtOCO–C ₆ H ₄	Bu	Pr	Pr	12c	96
17i	4-Cl–C ₆ H ₄	Cyclohexyl		–CH(Me)(CH ₂) ₃ CH(Me)–	12d	93
17h	3-CN–C ₆ H ₄	Ph(CH ₂) ₂		–(CH ₂) ₄ –	12e	91
17g	Mesityl	Bu	Et	Et	12f	93
17a	Ph	Bn	Bu	–	20a	99
17b	<i>p</i> -Tol	Bn	Pentyl	–	20b	93
17c	<i>p</i> -Tol	i-Pr	PhCH(Me)	–	20c	71
17e	Mesityl	Ph	i-Pr	–	20d	96
17j	<i>p</i> -Tol	2-Methylbutyl	Bn	–	20e	85
17k	4-Cl–C ₆ H ₄	(Furan-2-yl)methyl	Bu	--	20f	91

removed from the reaction mixture by washing with aqueous Na₂CO₃, followed by short column chromatography to give the desired guanidines.

Experimental Part

General. M.p.: hot-stage apparatus; uncorrected. NMR Spectra: in CDCl₃, or (D₆)DMSO with TMS as the internal standard for ¹H- (300 MHz) or a solvent as the internal standard for ¹³C-NMR (75 MHz). Column chromatography (CC): on silica gel (200–425 mesh) or on basic alumina (60–325 mesh). *Bis(1H-benzotriazol-1-yl)methanethione* (**15**) was prepared according to a previously reported procedure. M.p. 171–172°, yield 98%, ([35]; M.p. 170–171°, yield 90%).

General Procedure for the Preparation of Compounds 14a–14g [29]. Compounds **14a–14g** were prepared by adding Ph₃P to an ethereal solution of the corresponding azide. After the soln. was heated under reflux for 2 h, the solvent was removed under reduced pressure, and the residue was crystallized from abs. EtOH.

(Phenylimino)(triphenyl)phosphorane (14a). White microcrystals from EtOH (100%). M.p. 134–135° ([29]; 133–134°).

[(4-Methylphenyl)imino](triphenyl)phosphorane (14b). Yellow microcrystals from EtOH (99%). M.p. 136–137° ([29]; 136–137°).

3-[(Triphenyl-λ⁵-phosphanylidene)amino]benzotrionitrile (14c). White microcrystals from EtOH (96%). M.p. 159–160° ([29]; 157–158°).

Ethyl 4-[(Triphenyl-λ⁵-phosphanylidene)amino]benzoate (14d). White microcrystals from EtOH (85%). M.p. 136–137° ([36]; 136°).

[(4-Chlorophenyl)imino](triphenyl)phosphorane (14e). White microcrystals from EtOH (71%). M.p. 161–162° ([29]; 160–161°) [29].

N-(Triphenyl-λ⁵-phosphanylidene)benzamide (14f). White microcrystals from EtOH (98%). M.p. 194–195° (Lit. M.p. 195–196°) [37].

[(2,4,6-Trimethylphenyl)imino](triphenyl)phosphorane (14g). White microcrystals from EtOH (77%). M.p. 146–147° ([38]; 146–146.5°).

General Procedure for the Preparation of Compounds 13a–13f. To a stirred soln. of **15** (0.007 mol) in toluene (12 ml), the appropriate **14a–14f** (0.007 mol) was added at r.t., and the resulting mixture was heated at 60° for 4 h. Completion of the reaction was monitored by TLC. Then, the mixture was concentrated under reduced pressure, and the residue purified by gradient CC (AcOEt/hexanes) on silica gel to give **13a–13f**.

N-[Bis(1H-benzotriazol-1-yl)methylidene]aniline (13a). White microcrystals from AcOEt/hexanes (76%), M.p. 155–156°. ¹H-NMR (CDCl₃): 8.4 (*d*, *J* = 8.4, 1 H); 8.21 (*d*, *J* = 8.1, 1 H); 8.13–8.12 (*m*, 1 H); 7.75 (*t*, *J* = 7.4, 1 H); 7.60 (*t*, *J* = 7.7, 1 H); 7.41–7.38 (*m*, 2 H); 7.20–7.03 (*m*, 4 H); 6.8 (*d*, *J* = 8.2, 2 H). ¹³C-NMR (CDCl₃): 143.4; 130.2; 129.3; 129.2; 126.4; 126.3; 125.0; 121.2; 120.6; 114.3; 110.1. Anal. calc. for C₁₉H₁₃N₇: C 67.25, H 3.86, N 28.89; found: C 67.49, H 4.01, N 28.50.

N-[Bis(1H-benzotriazol-1-yl)methylidene]-4-methylaniline (13b). White microcrystals from AcOEt/hexanes (73%). M.p. 165–166°. ¹H-NMR (CDCl₃): 8.41 (*d*, *J* = 8.2, 1 H); 8.18 (*d*, *J* = 8.2, 1 H); 8.14–8.11

(*m*, 1 H); 7.75–7.70 (*m*, 1 H); 7.59–7.54 (*m*, 1 H); 7.41–7.38 (*m*, 2 H); 7.13–7.10 (*m*, 1 H); 6.96 (*d*, *J* = 9.0, 2 H); 6.73 (*d*, *J* = 9.0, 2 H). ¹³C-NMR (CDCl₃): 146.6; 144.8; 140.7; 136.3; 133.9; 132.4; 131.8; 130.1; 129.8; 129.3; 126.2; 125.0; 121.3; 120.5; 114.2; 110.1; 20.9. Anal. calc. for C₂₀H₁₃N₇: C 67.98, H 4.28, N 27.74; found: C 67.81, H 4.22, N 27.43.

3-[[Bis(1*H*-benzotriazol-1-yl)methylidene]amino]benzotrile (**13c**). Yellow microcrystals from AcOEt/hexanes (79%). M.p. 205–206°. ¹H-NMR (CDCl₃): 8.38 (*d*, *J* = 8.1, 1 H); 8.22 (*d*, *J* = 8.1, 1 H); 8.14 (*d*, *J* = 7.6, 1 H); 7.81–7.76 (*m*, 1 H); 7.63–7.59 (*m*, 1 H); 7.51–7.45 (*m*, 2 H); 7.37 (*d*, *J* = 7.7, 1 H); 7.30–7.24 (*m*, 2 H); 7.10 (*d*, *J* = 7.6, 1 H); 6.99 (*d*, *J* = 8.1, 1 H). ¹³C-NMR (CDCl₃): 146.8; 144.8; 144.6; 132.5; 131.5; 130.6; 130.2; 129.9; 129.4; 126.7; 125.5; 125.2; 124.9; 120.8; 117.8; 114.2; 113.4; 109.9. Anal. calc. for C₂₀H₁₂N₈: C 65.17, H 3.32, N 30.11; found: C 64.71, H 3.20, N 29.83.

Ethyl 4-[[Bis(1*H*-benzotriazol-1-yl)methylidene]amino]benzoate (**13d**). Yellow microcrystals from AcOEt/hexanes (53%). M.p. 197–198°. ¹H-NMR (CDCl₃): 8.46–8.36 (*m*, 1 H); 8.26–8.08 (*m*, 2 H); 7.88 (*d*, *J* = 8.5, 2 H); 7.81–7.71 (*m*, 1 H); 7.62 (br. *s*, 2 H); 7.43 (br. *s*, 1 H); 7.12 (br. *s*, 1 H); 6.92 (*d*, *J* = 8.5, 2 H); 4.31 (*q*, *J* = 7.1, 2 H); 1.35 (*t*, *J* = 7.1, 3 H). ¹³C-NMR (CDCl₃): 165.7; 147.6; 135.4; 130.8; 130.4; 127.9; 126.6; 125.3; 120.9; 120.7; 114.2; 110.0; 61.0; 14.22. Anal. calc. for C₂₂H₁₇N₇O₂: C 64.23, H 4.16, N 23.83; found: C 64.12, H 4.11, N 23.88.

[Bis(1*H*-benzotriazol-1-yl)methylidene](4-chlorophenyl)amine (**13e**). White microcrystals from AcOEt/hexanes (58%). M.p. 167–168°. ¹H-NMR (CDCl₃): 8.39 (*d*, *J* = 8.1, 1 H); 8.20 (*d*, *J* = 8.2, 1 H); 8.16–8.13 (*m*, 1 H); 7.78–7.73 (*m*, 1 H); 7.62–7.57 (*m*, 1 H); 7.45–7.42 (*m*, 2 H); 7.16–7.09 (*m*, 3 H); 6.79 (*d*, *J* = 8.7, 2 H). ¹³C-NMR (CDCl₃): 146.7; 144.8; 142.0; 135.0; 131.8; 130.3; 129.6; 129.4; 126.5; 125.2; 122.6; 120.7; 114.2; 110.0. Anal. calc. for C₁₉H₁₂ClN₇: C 61.05, H 3.24, N 26.23; found: C 60.95, H 3.11, N 26.02.

N-[[Bis(1*H*-benzotriazol-1-yl)methylidene]benzamide (**13f**) [28]. White needles from AcOEt/hexanes (86%). M.p. 108–109°. ¹H-NMR (CDCl₃): 8.40 (*d*, *J* = 8.2, 1 H); 8.23–8.16 (*m*, 4 H); 7.74–7.68 (*m*, 3 H); 7.61–7.56 (*m*, 4 H). ¹³C-NMR (CDCl₃): 166.7; 145.7; 133.6; 132.3; 131.7; 131.4; 130.4; 128.4; 126.3; 120.2; 114.8; 109.6.

General Procedure for the Preparation of Compounds 16a–16h. 1-Thiocarbamoyl-1*H*-benzotriazoles **16a–16h** were synthesized by the reaction of compound **15** (2 mmol) and the appropriate primary amine (2 mmol) in CH₂Cl₂ at r.t. for 18 h according to the procedure in [34]. M.p. and spectral data were used to characterize known **16a**, **16f**, and **16h**, and were found to be identical to reported values: **16a**: m.p. 108–109° ([38]: 108–109); **16f**: m.p. 72° ([38]: 72–73°); **16h**: m.p. 117° ([38]: 117–119°).

N-Isopropyl-1*H*-benzotriazole-1-carbothioamide (**16b**). White powder (95%). M.p. 107.7°. ¹H-NMR (CDCl₃): 8.84 (*d*, *J* = 8.5, 2 H); 8.00 (*d*, *J* = 8.2, 1 H); 7.57–7.52 (*m*, 1 H); 7.41–7.36 (*m*, 1 H); 4.67 (*sept.*, *J* = 7.0, 1 H); 1.36 (*d*, *J* = 6.4, 6 H). ¹³C-NMR (CDCl₃): 173.1; 147.0; 132.4; 130.1; 125.5; 120.1; 116.1; 47.0; 21.5. Anal. calc. for C₁₀H₁₂N₄S: C 54.52, H 5.49, N 25.43; found: C 54.55, H 5.49, N 25.27.

N-Phenyl-1*H*-benzotriazole-1-carbothioamide (**16c**). White powder (90%). M.p. 98.5°. ¹H-NMR (CDCl₃): 10.74 (*s*, 1 H); 8.94 (*d*, *J* = 8.5, 1 H); 8.13 (*d*, *J* = 8.4, 1 H); 7.77 (*d*, *J* = 8.0, 2 H); 7.70–7.65 (*m*, 1 H); 7.54–7.46 (*m*, 2 H); 7.38–7.32 (*m*, 1 H); 7.29–7.20 (*m*, 1 H). ¹³C-NMR (CDCl₃): 179.7; 137.1; 129.5; 129.4; 127.2; 126.9; 125.6; 125.1. Anal. calc. for C₁₃H₁₀N₄S: C 63.40, H 3.96, N 18.33; found: C 63.85, H 4.33, N 18.54.

N-Butyl-1*H*-benzotriazole-1-carbothioamide (**16d**). White powder (98%). M.p. 92.3°. ¹H-NMR (CDCl₃): 9.10 (br. *s*, 1 H); 8.92 (*d*, *J* = 8.5, 1 H); 8.09 (*d*, *J* = 8.2, 1 H); 7.64 (*t*, *J* = 7.7, 1 H); 7.47 (*t*, *J* = 7.87, 1 H); 3.85 (*dd*, *J* = 12.8, 7.0, 2 H); 1.83–1.75 (*m*, 2 H); 1.54–1.47 (*m*, 2 H); 1.01 (*t*, *J* = 7.3, 3 H). ¹³C-NMR (CDCl₃): 174.1; 147.0; 132.4; 130.2; 125.6; 120.2; 116.0; 44.8; 30.1; 20.2; 13.7. Anal. calc. for C₁₁H₁₄N₄S: C 56.38, H 6.02, N 23.81; found: C 56.74, H 6.40, N 23.47.

N-(2-Phenethyl)-1*H*-benzotriazole-1-carbothioamide (**16e**). White powder (93%). M.p. 110.2°. ¹H-NMR (CDCl₃): 9.18 (*s*, 1 H); 8.91 (*d*, *J* = 8.5, 1 H); 8.07 (*d*, *J* = 8.2, 1 H); 7.65–7.60 (*m*, 1 H); 7.48–7.43 (*m*, 1 H); 7.36–7.22 (*m*, 5 H); 4.10 (*t*, *J* = 7.1, 2 H); 3.11 (*t*, *J* = 7.1, 2 H). ¹³C-NMR (CDCl₃): 174.4; 147.0; 137.8; 132.3; 130.2; 128.8; 128.6; 126.9; 125.6; 120.2; 116.0; 46.1; 34.0. Anal. calc. for C₁₅H₁₄N₄S: C 63.80, H 5.00, N 19.84; found: C 63.92, H 4.98, N 19.59.

N-(2-Methylbutyl)-1*H*-benzotriazole-1-carbothioamide (**16g**). White powder (98%). M.p. 96°. ¹H-NMR (CDCl₃): 9.06 (*s*, 1 H); 8.91 (*d*, *J* = 8.5, 1 H); 8.10 (*d*, *J* = 8.2, 1 H); 7.64 (*t*, *J* = 7.5, 1 H); 7.47 (*t*, *J* = 7.4, 1 H); 1.97–1.93 (*m*, 1 H); 1.38–1.26 (*m*, 2 H); 1.06 (*d*, *J* = 6.7, 3 H); 1.01–0.99 (*m*, 3 H); 0.96–0.86 (*m*, 2 H). ¹³C-NMR (CDCl₃): 174.3; 146.9; 132.2; 130.1; 125.5; 120.0; 115.9; 50.6; 33.8; 27.1; 17.3; 11.1. Anal. calc. for C₁₂H₁₆N₄S: C 58.04, H 6.49, N 22.56; found: C 57.92, H 6.45, N 22.37.

General Procedure for the Preparation of Compounds 11a–11e. To a soln. of **13a–13e** (see Table 1; 0.85 mmol) in toluene (10 ml), the amine of choice (2.5 mmol) was added with stirring. The mixture was heated under reflux until full conversion of starting materials (1–2 h). Upon completion, the solvent was evaporated under reduced pressure. The crude product was dissolved in CH₂Cl₂, washed twice with sat. aq. Na₂CO₃, dried

(MgSO₄), and filtered. The solvent was removed under reduced pressure. The desired guanidines were isolated by flash CC on basic alumina (first AcOEt to remove impurities and MeOH to elute guanidine) to give **11a–11e**.

1,3-Dicyclohexyl-2-phenylguanidine (11a) [30]. Yellow oil (79%). ¹H-NMR (CDCl₃): 7.24–7.19 (m, 2 H); 7.03–6.98 (m, 3 H); 3.16–3.09 (m, 2 H); 1.91 (s, 2 H); 1.83–1.80 (m, 4 H); 1.61 (br. s, 4 H); 1.48 (br. s, 2 H); 1.23–1.15 (m, 5 H); 1.11–1.05 (m, 5 H). ¹³C-NMR (CDCl₃): 179.6; 153.6; 129.4; 124.2; 122.6; 52.2; 33.2; 25.0; 24.8; 24.7.

1,3-Dibutyl-2-(4-methylphenyl)guanidine (11b). Yellow oil (83%). ¹H-NMR (CDCl₃): 7.08 (d, *J* = 8.2, 2 H); 6.95 (d, *J* = 8.2, 2 H); 3.04 (t, *J* = 7.0, 4 H); 2.30 (s, 3 H); 1.95 (s, 2 H); 1.51 (quint., *J* = 7.4, 4 H); 1.26 (sext., *J* = 7.4, 4 H); 0.84 (t, *J* = 7.3, 6 H). ¹³C-NMR (CDCl₃): 179.2; 155.9; 134.5; 129.9; 122.1; 43.2; 31.3; 20.8; 19.8; 13.5. Anal. calc. for C₁₆H₂₇N₃: C 73.52, H 10.41, N 16.07; found: C 73.28, H 10.39, N 16.38.

2-(3-Cyanophenyl)-1,3-diisopropylguanidine (11c). Yellow oil (87%). ¹H-NMR ((D₆)DMSO): 8.81 (s, 1 H); 7.94 (s, 1 H); 7.57 (dd, *J* = 8.3, 1.0, 1 H); 7.42 (t, *J* = 8.0, 1 H); 7.31 (d, *J* = 7.6, 1 H); 6.33 (d, *J* = 7.4, 1 H); 3.76 (sept., *J* = 6.7, 2 H); 1.1 (d, *J* = 6.7, 12 H). ¹³C-NMR ((D₆)DMSO): 154.3; 141.5; 130.0; 124.3; 122.1; 119.9; 119.0; 111.4; 41.0; 22.8. Anal. calc. for C₁₄H₂₀N₄: C 73.74, H 8.25, N 22.93; found: C 73.89, H 8.30, N 23.54.

Ethyl 4-((Bis[1-phenylethyl]amino)methylidene)amino)benzoate (11d). Yellow oil (91%). ¹H-NMR (CDCl₃): 7.86–7.83 (m, 3 H); 7.34–7.21 (m, 3 H); 7.19–7.15 (m, 3 H); 6.96–6.93 (m, 4 H); 6.80 (d, *J* = 8.2, 1 H); 4.78 (q, *J* = 6.4, 1 H); 4.52 (q, *J* = 6.2, 1 H); 4.30–4.22 (m, 4 H); 1.40 (d, *J* = 6.7, 2 H); 1.33–1.27 (m, 7 H). ¹³C-NMR (CDCl₃): 166.3; 147.1; 143.4; 143.3; 131.0; 129.0; 128.8; 127.8; 127.5; 125.9; 125.6; 124.6; 122.3; 120.7; 60.7; 52.2; 23.6; 23.1; 14.3. Anal. calc. for C₂₆H₂₉N₃O₂: C 70.75, H 7.03, N 9.41; found: C 70.27, H 6.80, N 8.95.

1,3-Dibenzyl-2-(4-chlorophenyl)guanidine (11e). Yellow oil (85%). ¹H-NMR (CDCl₃): 7.24–7.22 (m, 6 H); 7.2 (d, *J* = 8.6, 2 H); 7.08–7.05 (m, 4 H); 6.81 (d, *J* = 8.6, 2 H); 4.18 (s, 4 H); 1.80 (s, 2 H). ¹³C-NMR (CDCl₃): 179.8; 154.6; 137.1; 129.4; 129.1; 128.8; 127.7; 127.0; 123.7; 46.5. Anal. calc. for C₂₁H₂₀ClN₃: C 68.09, H 5.76, N 10.21; found: C 68.41, H 5.94, N 10.50.

General Procedure for the Preparation of Compounds 19a–19e. To a soln. of appropriate **13** (see Table 1; 0.70 mmol) in toluene (10 ml), the corresponding diamine **18** (0.7 mmol) was added with stirring. The mixture was heated to reflux and kept at that temp. until the full conversion of starting materials (1–2 h). Upon completion, the solvent was evaporated under reduced pressure; crude product was dissolved in CH₂Cl₂, washed twice with sat. aq. Na₂CO₃, dried (MgSO₄), and filtered. The solvent was removed under reduced pressure. Desired guanidines were isolated by flash CC on basic alumina (first AcOEt to remove impurities and MeOH to elute guanidine) to give **19a–19e**.

4-Methyl-N-(3,4,5,6-tetrahydro-1H-pyrimidin-2-ylidene)benzenamine (19a). Colorless oil (95%). ¹H-NMR (CDCl₃): 7.2 (d, *J* = 8.2, 2 H); 7.07 (d, *J* = 8.2, 2 H); 3.37–3.33 (m, 4 H); 2.32 (s, 3 H); 1.98 (s, 2 H); 1.98–1.93 (m, 2 H). ¹³C-NMR (CDCl₃): 152.7; 136.5; 132.7; 130.5; 125.2; 38.4; 24.2; 20.9; 20.2. Anal. calc. for C₁₁H₁₃N₃: C 69.81, H 7.99, N 22.20; found: C 70.01, H 8.25, N 22.27.

N-(Imidazolidin-2-ylidene)-4-methylbenzenamine (19b) [32]. Yellow oil (95%). ¹H-NMR (CDCl₃): 7.13 (d, *J* = 8.2, 2 H); 7.06 (d, *J* = 8.2, 2 H); 3.66 (s, 4 H); 2.31 (s, 3 H); 1.94 (s, 2 H). ¹³C-NMR (CDCl₃): 159.6; 136.0; 134.1; 130.2; 123.1; 42.9; 20.8.

4-Chloro-N-[3,4,5,6-tetrahydro-5,5-dimethyl-1H-pyrimidin-2-ylidene]aniline (19c). Yellow oil (96%). ¹H-NMR (CDCl₃): 7.26 (d, *J* = 8.6, 2 H); 7.08 (d, *J* = 8.6, 2 H); 2.97 (s, 4 H); 1.91 (s, 2 H); 1.02 (s, 6 H). ¹³C-NMR (CDCl₃): 152.0; 134.1; 132.2; 130.1; 126.3; 50.1; 27.2; 24.1. Anal. calc. for C₁₂H₁₆ClN₃: C 60.63, H 6.78, N 17.68; found: C 60.78, H 6.55, N 17.77.

N-[3,4,5,6-Tetrahydro-1-methyl-1H-pyrimidin-2-ylidene]benzenamine (19d). Yellow oil (89%). ¹H-NMR (CDCl₃): 7.31–7.26 (m, 2 H); 7.08–7.03 (m, 1 H); 7.00 (d, *J* = 7.8, 2 H); 3.42–3.33 (m, 4 H); 2.75 (s, 3 H); 2.11–2.03 (m, 2 H); 1.99 (s, 1 H). ¹³C-NMR (CDCl₃): 154.4; 139.9; 129.4; 123.7; 121.1; 48.5; 39.6; 38.5; 21.8. Anal. calc. for C₁₁H₁₅N₃: C 69.81, H 7.99, N 22.20; found: C 69.98, H 7.75, N 22.57.

N-(3,4,5,6-Tetrahydro-1H-pyrimidin-2-ylidene)benzamide (19e) [33]. White microcrystals from AcOEt/hexanes (77%). M.p. 132–133°. ¹H-NMR (CDCl₃): 7.80 (d, *J* = 7.1, 2 H); 7.41–7.32 (m, 5 H); 3.41–3.49 (m, 4 H); 1.78–1.62 (m, 2 H). ¹³C-NMR (CDCl₃): 183.3; 168.2; 134.2; 131.5; 128.5; 127.0; 36.2; 29.8.

General Procedure for the Preparation of Compounds 17a–17l. To a stirred soln. of **16a–16h** (0.01 mol) in toluene (12 ml), the corresponding **14** (0.01 mol; see Table 2) was added at room temperature and the resulting mixture was heated at 110° for 1 h. Completion of the reaction was monitored by TLC. Upon completion, the reaction mixture was concentrated under reduced pressure and residue purified by gradient CC (AcOEt/hexanes) on silica gel to give **17a–17l**.

N-Benzyl-N'-phenyl-1H-benzotriazole-1-carboximidamide (17a). White microcrystals from AcOEt/hexanes (91%). M.p. 129–130°. ¹H-NMR (CDCl₃): 8.14 (br. s, 1 H); 8.06 (d, *J* = 8.2, 1 H); 7.51–7.46 (m,

1 H); 7.42–7.37 (*m*, 1 H); 7.32–7.22 (*m*, 7 H); 7.03–6.94 (*m*, 3 H); 6.53 (*br. s*, 1 H); 4.31 (*s*, 2 H). ¹³C-NMR (CDCl₃): 146.5; 141.0; 137.4; 131.6; 129.0; 128.9; 128.7; 127.8; 127.5; 125.0; 122.9; 121.6; 119.8; 114.5; 47.8. Anal. calc. for C₂₀H₁₇N₅: C 73.37, H 5.23, N 21.39; found: C 73.78, H 5.25, N 21.27.

N-Benzyl-*N'*-(4-methylphenyl)-1*H*-benzotriazole-1-carboximidamide (**17b**). Yellow oil (96%). ¹H-NMR (CDCl₃): 8.06 (*d*, *J* = 8.1, 1 H); 7.51–7.46 (*m*, 1 H); 7.42–7.37 (*m*, 1 H); 7.33–7.24 (*m*, 6 H); 7.05 (*d*, *J* = 7.1, 2 H); 6.86 (*d*, *J* = 7.1, 2 H); 6.45 (*br. s*, 1 H); 4.31 (*s*, 2 H); 2.30 (*s*, 3 H). ¹³C-NMR (CDCl₃): 143.9; 137.5; 134.6; 132.3; 131.7; 129.5; 129.2; 129.0; 128.7; 127.7; 127.5; 125.0; 121.4; 119.7; 115.3; 47.9; 20.8. Anal. calc. for C₂₁H₁₉N₅: C 73.88, H 5.61, N 19.90; found: C 73.83, H 5.96, N 19.85.

N-Isopropyl-*N'*-(4-methylphenyl)-1*H*-benzotriazole-1-carboximidamide (**17c**). Yellow oil (92%). ¹H-NMR (CDCl₃): 7.97 (*d*, *J* = 8.2, 1 H); 7.67–7.60 (*m*, 1 H); 7.45–7.28 (*m*, 2 H); 7.00 (*d*, *J* = 7.0, 2 H); 6.82 (*d*, *J* = 7.0, 2 H); 5.82 (*br. s*, 1 H); 3.61 (*br. s*, 1 H); 2.22 (*s*, 3 H); 1.08 (*d*, *J* = 6.2, 6 H). ¹³C-NMR (CDCl₃): 144.3; 132.3; 132.1; 131.7; 129.5; 128.8; 128.5; 128.4; 124.8; 121.1; 119.6; 44.5; 23.0; 20.8. Anal. calc. for C₁₇H₁₉N₅: C 69.60, H 6.53, N 23.87; found: C 69.40, H 6.38, N 23.62.

N'-(4-Chlorophenyl)-*N*-isopropyl-1*H*-benzotriazole-1-carboximidamide (**17d**). Yellow oil (67%). ¹H-NMR (CDCl₃): 8.06 (*d*, *J* = 8.2, 2 H); 7.51–7.46 (*m*, 1 H); 7.42–7.37 (*m*, 1 H); 7.20 (*d*, *J* = 8.2, 2 H); 6.90 (*d*, *J* = 8.0, 2 H); 6.02 (*br. s*, 1 H); 3.69 (*br. s*, 1 H); 1.19 (*d*, *J* = 6.3, 6 H). ¹³C-NMR (CDCl₃): 146.3; 145.6; 141.3; 131.5; 129.0; 128.9; 127.8; 125.0; 122.6; 119.8; 114.1; 44.6; 22.8. Anal. calc. for C₁₆H₁₆ClN₅: C 61.24, H 5.14, N 22.32; found: C 61.43, H 5.11, N 21.95.

N-Phenyl-*N'*-(2,4,6-trimethylphenyl)-benzotriazole-1-carboximidamide (**17e**). Yellow microcrystals from AcOEt/hexanes (80%). M.p. 140–141°. ¹H-NMR (CDCl₃): 8.42–8.40 (*m*, 1 H); 8.10 (*d*, *J* = 8.4, 1 H); 7.87 (*br. s*, 1 H); 7.59–7.54 (*m*, 1 H); 7.48–7.43 (*m*, 1 H); 7.02–6.85 (*m*, 3 H); 6.76–6.70 (*m*, 2 H); 6.66 (*s*, 1 H); 6.59 (*s*, 1 H); 2.23 (*s*, 3 H); 2.15 (*s*, 6 H). ¹³C-NMR (CDCl₃): 135.0; 132.3; 132.2; 131.5; 129.2; 128.7; 128.5; 128.4; 128.2; 127.7; 125.1; 123.1; 122.3; 120.5; 119.8; 20.6; 18.4 (2C). Anal. calc. for C₂₂H₂₁N₅: C 74.34, H 5.95, N 19.70; found: C 74.15, H 6.03, N 19.44.

Ethyl 4-[(1*H*-benzotriazol-1-yl)(butylamino)methylidene]amino]benzoate (**17f**). Yellow oil (53%). ¹H-NMR (CDCl₃): 8.00 (*d*, *J* = 8.2, 1 H); 7.96 (*d*, *J* = 8.2, 1 H); 7.87 (*d*, *J* = 8.4, 2 H); 7.42–7.37 (*m*, 1 H); 7.33–7.28 (*m*, 1 H); 6.91 (*d*, *J* = 8.2, 2 H); 6.40–6.30 (*m*, 1 H); 4.25 (*q*, *J* = 7.1, 2 H); 3.00 (*q*, *J* = 6.3, 2 H); 1.44 (*quint.*, *J* = 7.3, 2 H); 1.29 (*t*, *J* = 7.1, 3 H); 1.23 (*sext.*, *J* = 7.5, 2 H); 0.77 (*t*, *J* = 7.3, 3 H). ¹³C-NMR (CDCl₃): 166.4; 151.5; 146.3; 141.3; 131.4; 130.4; 129.1; 125.0; 124.4; 121.3; 119.7; 114.2; 60.6; 43.4; 31.5; 19.6; 14.2; 13.5. Anal. calc. for C₂₀H₂₃N₅O₂: C 65.73, H 6.34, N 19.16; found: C 65.63, H 6.77, N 18.90.

N-Butyl-*N'*-(2,4,6-trimethylphenyl)-1*H*-benzotriazole-1-carboximidamide (**17g**). Yellow oil (84%). ¹H-NMR (CDCl₃): 8.40 (*d*, *J* = 8.3, 1 H); 8.02 (*d*, *J* = 8.2, 1 H); 7.48–7.43 (*m*, 1 H); 7.38–7.33 (*m*, 1 H); 6.78 (*s*, 2 H); 6.28 (*br. s*, 1 H); 2.78 (*q*, *J* = 6.7, 2 H); 2.20 (*s*, 3 H); 2.11 (*s*, 6 H); 1.34 (*quint.*, *J* = 7.1, 2 H); 1.16 (*sext.*, *J* = 7.1, 2 H); 0.73 (*t*, *J* = 7.3, 3 H). ¹³C-NMR (CDCl₃): 146.7; 141.8; 139.5; 131.9; 131.7; 128.9; 128.2; 128.1; 124.9; 119.6; 115.5; 42.2; 32.1; 20.7; 19.7; 18.6 (2C); 13.4. Anal. calc. for C₂₀H₂₅N₅: C 71.61, H 7.51, N 20.53; found: C 71.90, H 7.80, N 20.19.

N'-(3-Cyanophenyl)-*N*-(2-phenylethyl)-1*H*-benzotriazole-1-carboximidamide (**17h**). Yellow oil (95%). ¹H-NMR (CDCl₃): 8.02 (*d*, *J* = 8.2, 1 H); 7.91 (*br. s*, 1 H); 7.50–7.45 (*m*, 1 H); 7.41–7.36 (*m*, 1 H); 7.32–7.24 (*m*, 5 H); 7.21–7.20 (*m*, 1 H); 7.12–7.10 (*m*, 3 H); 6.47 (*br. s*, 1 H); 3.45–3.43 (*m*, 2 H); 2.87 (*t*, *J* = 7.0, 2 H). ¹³C-NMR (CDCl₃): 147.7; 146.1; 141.8; 137.5; 131.2; 129.6; 129.1; 128.6; 128.6; 126.7; 126.1; 126.0; 125.0; 124.8; 119.8; 118.6; 113.6; 112.6; 44.6; 35.6. Anal. calc. for C₂₂H₁₈N₆: C 71.61, H 5.35, N 23.04; found: C 71.22, H 5.07, N 23.12.

N'-(4-Chlorophenyl)-*N*-cyclohexyl-1*H*-benzotriazole-1-carboximidamide (**17i**). Yellow oil (40%). ¹H-NMR (CDCl₃): 8.06 (*d*, *J* = 8.2, 2 H); 7.52–7.47 (*m*, 1 H); 7.42–7.37 (*m*, 1 H); 7.22 (*d*, *J* = 8.2, 2 H); 6.90 (*d*, *J* = 8.0, 2 H); 6.09 (*br. s*, 1 H); 3.30 (*br. s*, 1 H); 1.94–1.92 (*m*, 2 H); 1.74–1.66 (*m*, 2 H); 1.52 (*br. s*, 1 H); 1.32–1.09 (*m*, 5 H). ¹³C-NMR (CDCl₃): 146.4; 145.7; 141.2; 131.6; 129.0; 128.9; 127.8; 125.0; 122.6; 119.8; 114.2; 51.3; 33.0; 25.3; 24.4. Anal. calc. for C₁₉H₂₀ClN₅: C 63.13, H 5.70, N 18.79; found: C 62.70, H 5.65, N 18.91.

N-(2-Methylbutyl)-*N'*-(4-methylphenyl)-1*H*-benzotriazole-1-carboximidamide (**17j**). Yellow oil (82%). ¹H-NMR (CDCl₃): 8.06 (*d*, *J* = 8.2, 1 H); 7.51–7.46 (*m*, 1 H); 7.42–7.37 (*m*, 1 H); 7.07 (*d*, *J* = 7.1, 2 H); 6.89 (*br. s*, 2 H); 6.22 (*br. s*, 1 H); 3.08–2.90 (*m*, 2 H); 2.30 (*s*, 3 H); 1.62–1.45 (*m*, 1 H); 1.36–1.30 (*m*, 1 H); 1.17–1.08 (*m*, 1 H); 0.88 (*d*, *J* = 6.7, 3 H); 0.81 (*t*, *J* = 7.4, 3 H). ¹³C-NMR (CDCl₃): 144.2; 141.6; 132.0; 131.7; 129.4; 128.9; 126.1; 124.9; 121.3; 119.6; 117.9; 49.2; 35.1; 26.7; 20.8; 17.0; 11.0. Anal. calc. for C₁₉H₂₃N₅: C 71.00, H 7.21, N 21.79; found: C 71.15, H 7.45, N 21.65.

N'-(4-Chlorophenyl)-*N*-[(furan-2-yl)methyl]-1*H*-benzotriazole-1-carboximidamide (**17k**). Yellow oil (93%). ¹H-NMR (CDCl₃): 8.00 (*d*, *J* = 8.2, 2 H); 7.50–7.40 (*m*, 1 H); 7.35–7.30 (*m*, 1 H); 7.27 (*d*, *J* = 1.0, 1 H); 7.14 (*d*, *J* = 8.2, 2 H); 6.81 (*d*, *J* = 8.0, 2 H); 6.45 (*s*, 1 H); 6.23–6.21 (*m*, 1 H); 6.11 (*s*, 1 H); 4.26 (*s*, 2 H).

^{13}C -NMR (CDCl_3): 150.1; 145.0; 142.6; 141.2; 131.5; 129.2; 129.0; 128.7; 128.2; 125.1; 122.8; 120.0; 119.9; 110.4; 108.0; 40.8. Anal. calc. for $\text{C}_{18}\text{H}_{14}\text{ClN}_3\text{O}$: C 61.45, H 4.01, N 18.91; found: C 61.10, H 3.89, N 18.50.

N-Butyl-*N'*-(4-chlorophenyl)-1*H*-benzotriazole-1-carboximidamide (**17i**). Yellow oil (87%). ^1H -NMR (CDCl_3): 7.98 (*d*, $J = 8.2$, 1 H); 7.44–7.39 (*m*, 1 H); 7.34–7.25 (*m*, 1 H); 7.13 (*d*, $J = 8.3$, 2 H); 6.82 (*d*, $J = 8.1$, 2 H); 6.17 (*s*, 1 H); 3.03 (*br. s*, 2 H); 1.51–1.41 (*m*, 2 H); 1.28–1.18 (*m*, 2 H); 0.79 (*t*, $J = 7.3$, 3 H). ^{13}C -NMR (CDCl_3): 146.4; 145.6; 141.7; 131.5; 129.1; 128.8; 128.8; 127.7; 125.0; 122.8; 119.8; 43.5; 31.7; 19.7; 13.6. Anal. calc. for $\text{C}_{17}\text{H}_{18}\text{ClN}_3$: C 62.29, H 5.53, N 21.36; found: C 62.69, H 5.59, N 20.98.

General Procedure for the Preparation of Compounds 12a–12f. To a stirred soln. of appropriate **17** (see Table 3 for R and R¹; 1.6 mmol) in toluene (10 ml) was added the secondary amine (see Table 3 for R² and R³) of choice (1.6 mmol) at r.t. The reaction mixture was heated under reflux overnight. Completion of the reaction was monitored by TLC. Upon completion, the solvent was evaporated, and the residue was dissolved in CH_2Cl_2 . The soln. was washed twice with sat. aq. Na_2CO_3 and dried (MgSO_4), and the solvent was evaporated under reduced pressure. The desired guanidines **12a–12f** were purified by flash CC on basic alumina (first AcOEt to remove impurities and the MeOH to elute the guanidine).

3-Benzyl-1,1-diisopropyl-2-phenylguanidine (**12a**). Yellow oil (67%). ^1H -NMR (CDCl_3): 7.22–7.08 (*m*, 8 H); 6.89–6.85 (*m*, 2 H); 4.07 (*s*, 2 H); 3.77 (*sept.*, $J = 6.8$, 2 H); 1.89 (*s*, 2 H); 1.12 (*d*, $J = 6.9$, 12 H). ^{13}C -NMR (CDCl_3): 151.3; 150.0; 139.1; 129.3; 128.7; 127.4; 127.3; 123.5; 121.6; 46.0; 41.6; 31.8; 19.9. Anal. calc. for $\text{C}_{20}\text{H}_{27}\text{N}_3$: N 13.58; found: N 13.73.

N-Benzyl-*N'*-(4-methylphenyl)-4-morpholinecarboximidamide (**12b**). Yellow oil (93%). ^1H -NMR (CDCl_3): 7.26–7.16 (*m*, 3 H); 7.13–7.10 (*m*, 2 H); 6.91 (*d*, $J = 8.1$, 2 H); 6.76 (*br. s*, 1 H); 6.52 (*d*, $J = 8.1$, 2 H); 4.11 (*s*, 2 H); 3.67–3.64 (*m*, 4 H); 3.19–3.16 (*m*, 4 H); 2.17 (*s*, 3 H). ^{13}C -NMR (CDCl_3): 156.0; 151.2; 146.5; 138.8; 131.2; 129.8; 129.7; 128.6; 127.4; 127.3; 122.0; 66.7; 66.4; 49.3; 48.3; 46.9; 20.6; 0.9. Anal. calc. for $\text{C}_{19}\text{H}_{23}\text{N}_3\text{O}$: C 73.76, H 7.49, N 13.58; found: C 73.36, H 7.76, N 13.26.

Ethyl 4-[(Butylamino)(dipropylamino)methylidene]amino]benzoate (**12c**). Yellow oil (96%). ^1H -NMR (CDCl_3): 7.83 (*d*, $J = 8.5$, 2 H); 6.76 (*d*, $J = 8.5$, 2 H); 4.26 (*q*, $J = 7.1$, 2 H); 3.08 (*t*, $J = 7.4$, 4 H); 2.89 (*t*, $J = 7.0$, 2 H); 1.55–1.48 (*m*, 4 H); 1.40–1.28 (*m*, 5 H); 1.22–1.17 (*m*, 2 H); 0.82 (*t*, $J = 7.3$, 6 H); 0.79 (*t*, $J = 7.2$, 3 H). ^{13}C -NMR (CDCl_3): 166.9; 156.1; 130.9; 130.8; 129.7; 121.0; 60.4; 50.8; 44.5; 32.1; 21.4; 19.9; 14.4; 13.7; 11.4; 1.0. Anal. calc. for $\text{C}_{20}\text{H}_{33}\text{N}_3\text{O}_2 \cdot \text{HCl}$: C 62.96, H 9.33, N 10.14; found: C 63.24, H 9.75, N 9.91.

N'-(4-Chlorophenyl)-*N*-cyclohexyl-3,4,5,6-tetrahydro-2,6-dimethyl-2*H*-pyridine-2-carboximidamide (**12d**). Yellow oil (93%). ^1H -NMR ($(\text{D}_6)\text{DMSO}$): 7.41 (*d*, $J = 8.9$, 2 H); 7.24 (*d*, $J = 8.9$, 2 H); 6.30 (*d*, $J = 7.8$, 1 H); 3.51–3.45 (*m*, 1 H); 3.02–2.97 (*m*, 2 H); 1.80–1.64 (*m*, 7 H); 1.55–1.42 (*m*, 2 H); 1.33–1.10 (*m*, 3 H). ^{13}C -NMR ($(\text{D}_6)\text{DMSO}$): 154.3; 139.7; 128.4; 124.1; 118.8; 52.2; 47.49; 32.9; 30.1; 25.2; 24.3; 22.4; 19.4. Anal. calc. for $\text{C}_{20}\text{H}_{29}\text{ClN}_3 \cdot \text{HCl}$: N 10.93; found: N 11.13.

N'-(3-Cyanophenyl)-*N*-(2-phenylethyl)pyrrolidine-1-carboximidamide (**12e**). Yellow oil (91%). ^1H -NMR (CDCl_3): 7.32–7.21 (*m*, 4 H); 7.2 (*d*, $J = 6.9$, 2 H); 7.1 (*d*, $J = 7.6$, 1 H); 7.03–7.00 (*m*, 2 H); 4.95 (*br. s*, 1 H); 3.39–3.31 (*m*, 2 H); 3.16–3.11 (*m*, 4 H); 2.82–2.78 (*m*, 2 H); 1.83–1.79 (*m*, 4 H). ^{13}C -NMR (CDCl_3): 153.0; 138.5; 132.0; 129.5; 128.7; 128.6; 126.6; 126.5; 124.6; 123.2; 119.5; 112.3; 48.0; 44.7; 36.0; 25.3. Anal. calc. for $\text{C}_{20}\text{H}_{22}\text{N}_4$: C 75.44, H 6.96, N 17.59; found: C 75.62, H 7.19, N 17.28.

3-Butyl-1,1-diethyl-2-(2,4,6-trimethylphenyl)guanidine (**12f**). Yellow oil (93%). ^1H -NMR (CDCl_3): 6.73 (*s*, 2 H); 3.19 (*q*, $J = 7.0$, 4 H); 2.83 (*t*, $J = 7.0$, 2 H); 2.15–2.12 (*m*, 5 H); 1.97 (*s*, 6 H); 1.09 (*t*, $J = 7.0$, 6 H); 1.26–1.17 (*m*, 2 H); 0.75 (*t*, $J = 7.0$, 3 H). ^{13}C -NMR (CDCl_3): 154.9; 130.6; 129.6; 129.0; 128.6; 44.5; 42.6; 32.9; 20.7; 19.8; 18.3; 13.7; 12.8. Anal. calc. for $\text{C}_{18}\text{H}_{31}\text{N}_3$: C 74.69, H 10.79, N 14.32; found: C 74.68, H 10.91, N 13.88.

General Procedure for the Preparation of Compounds 20a–20f. To a soln. of the appropriate **17** (see Table 3 for R and R¹; 2.2 mmol) in toluene (10 ml), the amine (see Table 3 for R²; 2.2 mmol) was added with stirring. The reaction mixture was heated under reflux until full conversion of starting materials (TLC control). Upon completion, the solvent was evaporated under reduced pressure; the crude product was dissolved in CH_2Cl_2 , washed twice with sat. aq. Na_2CO_3 , dried (MgSO_4), and filtered. The solvent was removed under reduced pressure. The desired guanidines were isolated by flash CC on basic alumina (first AcOEt to remove impurities and MeOH to elute guanidine) to give **20a–20f**.

1-Benzyl-3-butyl-2-phenylguanidine (**20a**). Yellow oil (99%). ^1H -NMR (CDCl_3): 7.27–7.26 (*m*, 4 H); 7.21–7.16 (*m*, 3 H); 6.89–6.83 (*m*, 3 H); 4.30 (*s*, 2 H); 3.86 (*br. s*, 1 H); 3.03 (*t*, $J = 7.0$, 2 H); 1.34 (*quint.*, $J = 7.2$, 2 H); 1.16 (*sext.*, $J = 7.2$, 2 H); 0.79 (*t*, $J = 7.3$, 3 H). ^{13}C -NMR (CDCl_3): 151.3; 150.0; 139.1; 129.3; 128.7; 127.4; 127.3; 123.6; 121.6; 46.03; 41.6; 31.8; 19.9; 13.7. Anal. calc. for $\text{C}_{18}\text{H}_{23}\text{N}_3$: C 76.43, H 8.95, N 14.93; found: C 75.84, H 8.50, N 14.76.

1-Benzyl-3-pentyl-2-(4-methylphenyl)guanidine (two tautomers; **20b**). Yellow oil (93%). ^1H -NMR (CDCl_3): 7.26–7.17 (*m*, 5 H); 7.00 (*d*, $J = 8.0$, 2 H); 6.81 (*d*, $J = 8.2$, 2 H); 4.29 (*s*, 2 H); 2.90 (*t*, $J = 6.9$, 2 H);

2.29 (s, 3 H); 1.96 (s, 3 H) 1.44–1.34 (m, 2 H); 1.26–1.10 (m, 3 H); 1.05–0.87 (m, 1 H); 0.84–0.74 (m, 4 H). ¹³C-NMR (CDCl₃): 179.3; 155.6; 155.4; 137.5; 133.7; 133.7; 129.7; 128.5; 128.5; 127.4; 127.0; 127.0; 122.1; 48.8; 46.1; 43.1; 34.6; 28.8; 28.5; 26.5; 24.4; 22.0; 20.6; 16.7; 13.7; 10.8. Anal. calc. for C₂₀H₂₇N₃: C 77.63, H 8.79, N 13.58; found: C 77.58, H 8.43, N 13.61.

1-Isopropyl-2-(4-methylphenyl)-3-(1-phenylethyl)guanidine (20c). Yellow oil (71%). ¹H-NMR (CDCl₃): 7.38–7.21 (m, 5 H); 7.09–7.06 (m, 2 H); 6.79 (d, *J* = 7.8, 2 H); 4.62–4.60 (m, 1 H); 3.76 (br. s, 1 H); 2.30 (s, 3 H); 1.39–1.37 (m, 3 H); 1.08 (d, *J* = 6.3, 3 H); 0.90 (d, *J* = 6.3, 3 H). ¹³C-NMR (CDCl₃): 151.3; 144.5; 129.9; 128.8; 128.6; 127.4; 125.7; 125.6; 123.2; 118.8; 43.0; 23.8; 23.3; 22.8; 20.8. Anal. calc. for C₁₉H₂₅N₃: C 77.85, H 8.61, N 13.54; found: C 77.63, H 8.44, N 13.10.

1-Isopropyl-2-mesityl-3-phenylguanidine (20d). Yellow oil (96%). ¹H-NMR (CDCl₃): 7.27–7.19 (m, 3 H); 7.06–6.99 (m, 3 H); 6.81 (s, 1 H); 3.74 (br. s, 1 H); 2.19 (s, 3 H); 2.16 (s, 6 H); 1.93 (s, 1 H); 1.00 (d, *J* = 6.6, 6 H). ¹³C-NMR (CDCl₃): 151.1; 138.9; 129.5; 129.3; 128.8; 124.7; 123.9; 123.4; 114.9; 43.7; 23.0; 20.8; 18.1. Anal. calc. for C₁₉H₂₅N₃: C 77.85, H 8.61, N 13.54; found: C 77.70, H 8.46, N 13.09.

1-Benzyl-3-(2-methylbutyl)-2-(4-methylphenyl)guanidine (20e). Yellow oil (85%). ¹H-NMR (CDCl₃): 7.36–7.25 (m, 5 H); 7.06 (d, *J* = 8.1, 2 H); 6.91 (d, *J* = 8.1, 2 H); 4.30 (s, 2 H); 2.85 (dd, *J* = 3.0, 6.0, 1 H); 2.71 (dd, *J* = 13.0, 7.1, 1 H); 2.28 (s, 3 H); 1.99 (s, 2 H); 1.52–1.40 (m, 1 H); 1.23–1.18 (m, 1 H); 1.03–0.96 (m, 1 H); 0.74 (d, *J* = 7.4, 3 H); 0.73 (d, *J* = 7.4, 3 H). ¹³C-NMR (CDCl₃): 156.3; 137.0; 134.8; 130.0; 129.0; 128.0; 127.1; 124.9; 122.5; 49.4; 46.7; 34.8; 26.6; 20.8; 16.9; 11.0. Anal. calc. for C₂₀H₂₇N₃·HCl: N 12.15; found: N 11.78.

1-Butyl-2-(4-chlorophenyl)-3-(2-furylmethyl)guanidine (20f). Yellow oil (91%). ¹H-NMR (CDCl₃): 7.38–7.37 (m, 1 H); 7.23 (d, *J* = 8.5, 2 H); 6.89 (d, *J* = 8.5, 2 H); 6.34–6.33 (m, 1 H); 6.28–6.27 (m, 1 H); 4.42 (s, 2 H); 3.15 (t, *J* = 7.1, 2 H); 1.52–1.44 (m, 2 H); 1.34–1.26 (m, 2 H); 0.85 (t, *J* = 7.3, 3 H). ¹³C-NMR (CDCl₃): 152.5; 151.2; 142.4; 129.5; 129.4; 124.7; 124.0; 110.5; 107.8; 42.3; 39.4; 31.5; 19.9; 13.7. Anal. calc. for C₁₆H₂₀ClN₃O·HCl: C 56.15, H 6.18, N 12.28; found: C 56.28, H 6.20, N 12.36.

REFERENCES

- [1] R. G. S. Berlinck, *Nat. Prod. Rep.* **1999**, *16*, 339; L. Heys, C. G. Moore, P. J. Murphy, *J. Chem. Soc. Rev.* **2000**, *29*, 57.
- [2] O. E. Levy, J. E. Semple, M. L. Lim, J. Reiner, W. E. Rote, E. Dempsey, B. M. Richard, E. Zhang, A. Tulinsky, W. C. Ripka, R. F. Nutt, *J. Med. Chem.* **1996**, *39*, 4527; M. J. Rynkiewicz, B. A. Seaton, *Biochem. J.* **1996**, *35*, 16174.
- [3] I. J. McAlpine, R. W. Armstrong, *Tetrahedron Lett.* **2000**, *41*, 1849.
- [4] V. D. Le, C. H. Wong, *J. Org. Chem.* **2000**, *65*, 2399.
- [5] C. G. Silva, E. Parolo, E. L. Streck, M. Wajner, C. M. D. Wannmacher, A. T. Wyse, *Brain Res.* **1999**, *838*, 78.
- [6] N. L. Reddy, W. Fan, S. S. Magar, M. E. Perlman, E. Yost, L. Zhung, D. Berlove, J. B. Fischer, K. B. Howie, T. Wolcott, G. J. Durant, *J. Med. Chem.* **1998**, *41*, 3298.
- [7] P. W. Smith, S. L. Sollis, P. D. Howes, P. C. Cherry, I. D. Starkey, K. N. Cobley, H. Weston, J. Scieszka, A. Merritt, A. Whittington, P. Wyatt, N. Taylor, D. Green, R. Bethell, S. Madar, R. J. Fenton, P. J. Morley, T. Pateman, A. Beresford, *J. Med. Chem.* **1998**, *41*, 787.
- [8] A. R. Katritzky, B. Rogovoy, *Arkivoc* **2005**, *Part iv*, 49.
- [9] K. Wermann, M. Walther, E. Anders, *Arkivoc* **2002**, *24*; T. Genski, G. Macdonald, X. Wei, N. Lewis, R. J. K. Taylor, *Arkivoc* **2000**, 266.
- [10] D. H. R. Barton, J. D. Elliott, S. D. Gero, *J. Chem. Soc., Perkin Trans. 1.* **1982**, 2085.
- [11] K. Feichtinger, C. Zapf, H. L. Sings, M. Goodman, *J. Org. Chem.* **1998**, *63*, 3804.
- [12] M. S. Bernatowicz, Y. Wu, G. R. Matsueda, *Tetrahedron Lett.* **1993**, *34*, 3389.
- [13] C. A. Maryanoff, R. C. Stanzione, J. N. Plampin, J. E. Mills, *J. Org. Chem.* **1986**, *51*, 1882.
- [14] D. R. Kent, W. L. Cody, A. M. Doherty, *Tetrahedron Lett.* **1996**, *37*, 8711.
- [15] Z. X. Guo, A. N. Cammidge, D. C. Horwell, *Synth. Commun.* **2000**, *30*, 2933.
- [16] K. S. Kim, L. Qian, *Tetrahedron Lett.* **1993**, *34*, 7677.
- [17] C. Levallet, J. Lerpiniere, S. Y. Ko, *Tetrahedron Lett.* **1997**, *53*, 5251.
- [18] E. J. Iwanowicz, M. A. Poss, J. Lin, *Synth. Commun.* **1993**, *23*, 1443.
- [19] Y. F. Yong, J. A. Kowalski, M. A. Lipton, *J. Org. Chem.* **1997**, *62*, 1540.
- [20] M. A. Poss, E. Iwanowicz, J. A. Reid, J. Lin, Z. Gu, *Tetrahedron Lett.* **1992**, *33*, 5933.
- [21] C. R. Rasmussen, F. J. Villani, L. E. Weaner, B. E. Reynolds, A. R. Hood, L. R. Hecker, S. O. Nortey, A. Hanslin, M. J. Costanzo, E. T. Powell, A. J. Molinari, *Synthesis* **1988**, *23*, 456.

- [22] C. R. Rasmussen, F. J. Villani, B. E. Reynolds, J. N. Plampin, A. R. Hood, L. R. Hecker, S. O. Nortey, A. Hanslin, M. J. Costanzo, R. M. Howse, A. J. Molinari, *Synthesis* **1988**, 23, 460.
- [23] Y. Q. Wu, S. K. Hamilton, D. E. Wilkinson, G. S. Hamilton, *J. Org. Chem.* **2002**, 67, 7553.
- [24] P. Molina, M. Alajarin, J. Saez, *Synth. Commun.* **1983**, 13, 67.
- [25] A. R. Katritzky, R. L. Parris, S. M. Allin, *Synth. Commun.* **1995**, 25, 1173.
- [26] A. R. Katritzky, B. Rogovoy, C. Klein, H. Insuasty, V. Vvedensky, B. Insuasty, *J. Org. Chem.* **2001**, 66, 2854.
- [27] A. R. Katritzky, B. V. Rogovoy, V. Vvedensky, *J. Org. Chem.* **2000**, 65, 8080.
- [28] A. R. Katritzky, B. V. Rogovoy, X. Cai, N. Kirichenko, K. V. Kovalenko, *J. Org. Chem.* **2004**, 69, 309.
- [29] A. W. Johnson, S. C. K. Wong, *Can. J. Chem.* **1966**, 44, 2793.
- [30] D. F. Gavin, W. J. Schnabel, E. Kober, M. Roninson, *J. Org. Chem.* **1967**, 32, 2511.
- [31] M. Mikolajczyk, P. Kielbasinski, *Tetrahedron* **2000**, 37, 233.
- [32] A. Trani, E. Bellasio, *J. Heterocycl. Chem.* **1974**, 11, 257.
- [33] J. Burkhardt, K. Hamann, *Chem. Ber.* **1967**, 100, 2569.
- [34] A. R. Katritzky, S. Ledoux, R. M. Witek, S. K. Nair, *J. Org. Chem.* **2004**, 69, 2976.
- [35] C. Larsen, K. Steliou, D. N. Harpp, *J. Org. Chem.* **1978**, 43, 337.
- [36] E. M. Briggs, *Synthesis* **1980**, 295.
- [37] P. Laszlo, *Tetrahedron Lett.* **1984**, 25, 4651.
- [38] V. N. Fetyukhin, *Zh. Obshch. Khim.* **1983**, 53, 1763.

Received March 1, 2005